Feature | March 19, 2013

Endovascular Pulmonary Embolism Therapy Shows Promise Over Medical Therapy Alone

ekos, pulmonary embolism, clot busting

March 19, 2013 — Results of the ULTIMA trial using endovascular therapy to treat submassive pulmonary embolism (PE) were presented at the American College of Cardiology 2013 meeting, The trial is the first randomized controlled trial comparing the use of an endovascular approach along with anticoagulation vs. anticoagulation therapy alone, the current standard of care.



Dr. Nils Kucher, a cardiologist at the University Hospital Bern, Switzerland, and principal investigator, reported on the 59-patient study conducted at eight and European centers. Of the 59 patients, 30 were randomly selected and treated with Ekos catheters, a device that generates ultrasound energy while simultaneously delivering a clot-dissolving drug. The advantage of this combination is that the ultrasound conditions the clot resulting in more effective drug delivery; thus ensuring faster and more complete clot dissolution. All 59 patients’ heart function were measured pre and 24 hours post therapy. Patients in the Ekos group demonstrated statistically significant reduction in right heart enlargement with no adverse effects from the catheterization. There were no serious bleeding events in either group. There was one death in the non-Ekos group for reasons other than PE.


Patients with submassive PE typically have a major clot in one or both pulmonary arteries that interferes with the heart’s ability to pump blood into the lungs for oxygenation, causing enlargement of the right side of the heart. Not removing the clot burden may quickly result in right heart failure and death, or permanent pulmonary hypertension. Anticoagulation therapy does little to dissolve clots, but rather helps prevent further clots from forming.


“ULTIMA is a pivotal study showing efficacy and safety of treating intermediate risk PE with a standardized interventional approach,” Kucher said.


The average 24-hour improvement in right heart dysfunction among the Ekos treated patients, as measured using a heart parameter called RV/LV ratio, was 23 percent, compared to anticoagulation treated patients whose average improvement was only 3 percent. This difference is both clinically and statistically significant (p<0.0001). While patients treated with anticoagulation alone will generally improve over time, the Ekos-treated patients continued to show a statistically significant (p<0.0001) greater reduction in right heart dysfunction at 90 days than patients treated with just anticoagulation.


“It is not unlikely that the ULTIMA study may be the beginning of a treatment paradigm shift for PE similar to what was seen two decades ago for acute coronary syndrome,” Kucher added. “We used to treat acute myocardial infarction with intravenous clot dissolving drugs; yet, today this drug therapy has almost exclusively been replaced by endovascular treatment with balloons and stents. ULTIMA promises to start a similar revolution for the treatment of PE patients at increased risk of death, changing management from IV drug therapy to an endovascular approach which may be safer.”


Samuel Z. Goldhaber, M.D., professor of medicine, Harvard Medical School and director, venous thromboembolism research group, Brigham and Woman’s Hospital, Boston, and principal investigator for the SEATTLE II study. The 150-patient, single arm, prospective trial studied Ekos-treated patients suffering from massive and submassive PE. “The results of the ULTIMA trial clearly demonstrate that physicians now have another tool in their armamentarium for the safe and effective treatment of submassive PE,” he said.


For more information: www.ekoscorp.com


Related Content

Videos | Cardiovascular Ultrasound| June 26, 2015
Interview at the American Society of Echocardiography (ASE) annual meeting with Federico Asch, M.D., M.D., FACC, FASE
STEMI, ultrasound to treat heart attacks, ultrasound to treat STEMI
Feature | Thrombectomy Devices| June 12, 2015
Breakthrough Research Demonstrates Contrast Ultrasound Can be Used as Heart Attack Treatment 
Aspire, thrombectomy, C. Dorn Smith, aspirators, clot, cold leg, removal

Clot in femoral artery caused by atrial fibrillation

News | Thrombectomy Devices| June 11, 2015
C. Dorn Smith, M.D., vascular surgeon in Kingstree, South Carolina, was successful in using a new device to remove...
Penumbra, ACE64, aspiration thrombectomy, acute ischemic stroke, FDA
Technology | June 05, 2015
Penumbra Inc. announced that the company’s ACE64 aspiration thrombectomy system received 510(k) marketing clearance...
Medtronic, SWIFT PRIME, REVASCAT, Solitaire, stent thrombectomy, stroke
News | April 30, 2015
Two global trials have found that the addition of the Solitaire device stent thrombectomy procedure to current...
Aspire, Pablo Uceda, DFW Vascular, deep vein thrombosis, thrombectomy
News | March 12, 2015
Pablo Uceda, M.D., vascular surgeon with DFW Vascular, Dallas, Texas, was successful in using a new device to clear...
VTEC, NYU Langone, venous therapies, deep vein thrombosis, DVT, PE
Feature | March 09, 2015
NYU Langone Medical Center has announced the creation of a new multidisciplinary Venous Thromboembolic Disease Center (...
Covidien, Trellis peripheral infusion system, FDA recall, balloon inflation port
News | February 12, 2015
A manufacturing error caused the balloon inflation ports to be mislabeled on Covidien’s Trellis 6 and Trellis 8...
Covidien, Solitaire, stent thrombectomy, trial, Netherlands

Image courtesy of Covidien Ltd.

Feature | December 19, 2014
In a landmark study evaluating the addition of stent thrombectomy clot removal to pharmaceutical treatment for patients...
Ekos for PE

The Ekos catheter was recently cleared by the FDA to aid in infusion and in breaking down pulmonary emboli faster than traditional lytic treatment alone.

Feature | October 03, 2014 | James M. McCabe, M.D., FACC, University of Washington, Seattle
Acute intermediate-risk pulmonary emboli (PE) in normotensive patients with right ventricle dysfunction present the...
Overlay Init